Skip to main content
SamsungInvestment

Samsung Electronics Invests in Samsung Biologics Rights Offering

Source: Autobound Signal API · 136 signals tracked for Samsung · updated

Get Samsung's live signals in Claude or ChatGPT, or by API

AskWhat changed at Samsung this week? Use Autobound signals for samsung.com.

What happened

Samsung Electronics will invest 666.2 billion won to participate in Samsung Biologics' paid-in capital increase.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Samsung Electronics will participate in a paid-in capital increase by Samsung Biologics, investing 666.2 billion won (about $500 million). Samsung Electronics disclosed on Oct. 29 that it held a board of directors meeting and resolved the agenda to acquire 567,503 common shares of Samsung Biologics. This investment represents participation as an existing shareholder in a paid-in capital increase of approximately 3 trillion won pursued by Samsung Biologics. As of the end of the first half of this year, Samsung Electronics is the second-largest shareholder, holding a 31.22% stake in Samsung Biologics. Samsung Electronics will subscribe to the entire volume (100%) of its allocated new shares. The scheduled payment date for the shares is on Nov. 17. Samsung C&T, the largest shareholder with a 43.06% stake, also decided to invest 919 billion won to purchase 782,818 shares of Samsung Biologics. However, the investment amount was calculated based on the issue price per share of the new shares for the paid-in capital increase, which Samsung Biologics disclosed on Oct. 1. The amount is subject to change depending on the final issue price, which will be determined on Nov. 5.

businesskorea.co.kr/news/articleView.htmlRead the full source

Extracted by Autobound

From the Signal API record
Event
Investment

What this signalsAn investment often shows where the company plans to grow.

Takes effect
Nov 17, 2026
Financing type
Equity

Companies

  • Samsung BiologicsRelated companysamsungbiologics.com

More investment signals at other companies

The full record

From the Signal API record

Numbers

Amount (USD)
$498M

Extraction

Confidence
95%
Detected
Oct 29, 2026
signal_type
news
signal_subtype
invests_into

Use this data

Get every investment signal for Samsung and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Samsung this week?”

  2. Send it to your own tools

    The Signal API returns investment signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/22c69357-00a3-7554-29ab-d0ae35affe47 returns this record as JSON. POST /v1/companies/enrich returns every signal for samsung.com.

{
  "signal_id": "22c69357-00a3-7554-29ab-d0ae35affe47",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-10-29T12:06:04+00:00",
  "company": {
    "name": "Samsung",
    "domain": "samsung.com"
  },
  "data": {
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=280015",
    "title": "Samsung Electronics Invests in Samsung Biologics Rights Offering - Businesskorea",
    "excerpt": "Samsung Electronics will participate in a paid-in capital increase by Samsung Biologics, investing 666.2 billion won (about $500 million). Samsung Electronics disclosed on Oct. 29 that it held a board of directors meeting and resolved the agenda to acquire 567,503 common shares of Samsung Biologics. This investment represents participation as an existing shareholder in a paid-in capital increase of approximately 3 trillion won pursued by Samsung Biologics. As of the end of the first half of this year, Samsung Electronics is the second-largest shareholder, holding a 31.22% stake in Samsung Biologics. Samsung Electronics will subscribe to the entire volume (100%) of its allocated new shares. The scheduled payment date for the shares is on Nov. 17. Samsung C&T, the largest shareholder with a 43.06% stake, also decided to invest 919 billion won to purchase 782,818 shares of Samsung Biologics. However, the investment amount was calculated based on the issue price per share of the new shares for the paid-in capital increase, which Samsung Biologics disclosed on Oct. 1. The amount is subject to change depending on the final issue price, which will be determined on Nov. 5.",
    "summary": "Samsung Electronics will invest 666.2 billion won to participate in Samsung Biologics' paid-in capital increase.",
    "planning": true,
    "image_url": "https://www.businesskorea.co.kr/news/thumbnail/202610/280015_287777_435_v150.jpg",
    "confidence": 0.95,
    "published_at": "2026-10-29T12:06:04Z",
    "effective_date": "2026-11-17",
    "article_sentence": "Samsung Electronics will participate in a paid-in capital increase by Samsung Biologics, investing 666.2 billion won (about $500 million).",
    "amount_normalized": 498171036,
    "financing_type_tags": [
      "equity"
    ],
    "related_company_name": "Samsung Biologics",
    "related_company_domain": "samsungbiologics.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.